

List of New Drugs approved in the year 2024 till date

S.No	Name of drug	Indication	Date of issue
1.	Tirzepatide 2.5mg /0.5ml, 5mg/0.5ml, 7.5mg/0.5 ml,10mg/0.5 ml,12.5mg/0.5 ml,15mg/0.5 ml solution for injection in a prefilled pen	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus	19-01 2024
2.	Plazomicin injection 500mg/10ml (50mg/ml)	Indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganism(s) <ul style="list-style-type: none"> • Escherichia coli, • Klebsiella pneumoniae, • Proteus mirabilis, and • Enterobacter cloacae 	02-02-2024
3.	Etifoxine Hydrochloride Bulk drug & Etifoxine Hydrochloride capsules 50 mg	Indicated for psychosomatic manifestations of anxiety	21-03-2024
4.	Vonoprazan fumarate Bulk drug& Vonoprazan tablets 10mg/20 mg	<ul style="list-style-type: none"> • Treatment of reflux esophagitis(RE) • Treatment of gastric ulcer (GU) • Treatment of duodenal ulcer(DU) • Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration. • Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration. • Adjunct to Helicobacter pylori eradication associated with: Gastric ulcer, Duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage cancer, or Helicobacter pylori gastritis. 	08-05-2024

5.	rdESAT-6 and rCFP-10 (Cy-Tb) injection (Additional indication)	<ul style="list-style-type: none"> • For Detection of Latent-TB for population of age group 1 year and above. • For detection of Latent-TB for population below 1 year in implementation research mode under National program only. 	16-05-2024
6.	Selpercatinib Capsules 40 mg & 80mg	<ul style="list-style-type: none"> • Adult patients with metastatic RET fusion-positive non-small cell lung cancer(NSCLC) • Adult and pediatric patients 12 years of age and older with advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy. • Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory(if radioactive iodine is appropriate) 	16-05-2024